Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04943653
Other study ID # KC20MISF0813
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 8, 2021
Est. completion date December 2025

Study information

Verified date July 2021
Source Seoul St. Mary's Hospital
Contact Kabsoo Shin
Phone 82-2-2258-6256
Email kabsoo.shin@catholic.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with peritoneal metastasis. Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy with systemic capecitabine and oxaliplatin in advanced gastric cancer with peritoneal metastasis.


Recruitment information / eligibility

Status Recruiting
Enrollment 61
Est. completion date December 2025
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility 1. Inclusion Criteria: - ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1 - pathologically proven primary gastric adenocarcinoma - peritoneal metastasis confirmed by laparoscopy or diagnostic imaging - written informed consent - adequate function of important organs (within 14 days before registration) Absolute neutrophil count =1.5 x 10^9/L, Platelet >=100,000/mm3, Hemoglobin >=8.0g/dL, Total bilirubin <= = 2.0mg/dl or ULN(Upper Limit of Normal) x 1.5, AST(aspartate aminotransferase) <=100IU/L(International Unit/Liter), ALT(alanine transaminase) <=100IU/L, Creatinine clearance = 50mL/min (milliliter/minute), 2. Exclusion Criteria: - other active concomitant malignancies - HER2(human epidermal growth factor receptor 2) positive (Immunohistochemistry 3+ or 2+ with in situ hybridization positive) - no investigational anticancer therapy within 30 days prior to the first dose of study treatment - recent (within 6 months) acute coronary syndrome, severe heart failure or severe pulmonary disease - uncontrolled acute or chronic disease - uncontrolled infection or inflammation - uncontrolled psychiatric disorder or central neurologic disease - not fully recovered from previous surgery - prior anticancer therapy (chemotherapy, immunotherapy, radiation) within 6 months - intolerable to oral administration or a lack of physical integration of the upper gastrointestinal tract or with a malabsorption syndrome - fertile males and females who are unwilling to use effective contraceptive methods. - pregnancy, breast feeding or intention to become pregnant - interstitial pneumonia or pulmonary fibrosis - peripheral neuropathy with functional impairment - hypersensitivity to paclitaxel, oxaliplatin, capecitabine, fluoropyrimidine or Cremophor EL. - concomitant therapy with any substrate or inhibitor of Cytochrome P450 2C8 or 3A4 - concomitant therapy with sorivudine or brivudine - Dihydropyrimidine dehydrogenase (DPD) deficiency. - current or recent (within the 7 days prior to enrollment) treatment of tegafur-gimeracil-oteracil potassium

Study Design


Intervention

Drug:
Paclitaxel
intraperitoneal paclitaxel 20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I) recommended dose (phase II)

Locations

Country Name City State
Korea, Republic of Gastric cancer center, Seoul St. Mary's Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul St. Mary's Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-month progression free survival (6-month PFS) PFS is the time from date of first dose until the date of objective disease progression or death 6 months after start of treatment
Secondary 1-year overall survival (1-year OS) OS is the time from date of first dose until death due to any cause 1 year after start of treatment
Secondary Objective Response Rate (ORR) Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed. 6 months after start of treatment
Secondary Conversion surgery rate rate of conversion surgery 6 months after start of treatment
Secondary Ascites response negative conversion rate of peritoneal cytology 6 months after start of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4